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King’s College Hospital, Denmark Hill, King’s College London, London, UKSummary suppressive (IS) drugs. However, transplant recipients stillDespite the increase in long-term survival, liver transplant recip-
ients still exhibit higher morbidity and mortality than the general
population. This is in part attributed to the lifelong administration
of immunosuppression and its associated side effects. Several
studies reported in the last decades have evaluated the impact
of immunosuppression minimization in liver transplant recipi-
ents, but results have been inconsistent due to the heterogeneity
of study designs and insufﬁcient sample sizes. On the other hand,
complete immunosuppression withdrawal has proven to be feasi-
ble in approximately 20% of carefully selected liver transplant
recipients, especially in older patients and those with longer dura-
tion after transplantation. The long-term risks and clinical bene-
ﬁts of this strategy, however, also need to be clariﬁed. As a
consequence, and despite the general perception that a large pro-
portion of liver recipients are over-immunosuppressed, it is cur-
rently not possible to derive evidence-based guidelines on how
to manage long-term immunosuppression to improve clinical
outcomes. Large clinical trials of drug minimization and/or with-
drawal focused on clinically-relevant long-term outcomes are
required. Development of personalized medicine tools and a dee-
per understanding of the pathogenesis of idiopathic inﬂammatory
graft lesions will be pre-requisites to achieve these goals.
 2013 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver. Open access under 
CC BY-NC-ND license.Background
Long-term survival after solid organ transplantation has
increased during the last decades [1] due to improvements in sur-
gical technique, peri-operative care, and more efﬁcient immuno-Journal of Hepatology 20
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tion [2]. One of the main causes are co-morbidities negatively
inﬂuenced by chronic IS drug usage [3–8]. The high prevalence
of IS related toxicity and the fact that liver allograft rejection sel-
dom impacts on clinical outcomes suggest that most liver recip-
ients are likely to be over-immunosuppressed [9,10]. One of the
most signiﬁcant side effects of IS drugs is calcineurin inhibitor
(CNI) nephrotoxicity, which contributes to the high rate of
chronic renal failure observed in liver transplant recipients and
is associated with the need to institute renal replacement thera-
pies and with high mortality [11,12]. Minimization (or complete
withdrawal) of immunosuppression, particular CNIs, may over-
come these problems. The clinical opportunity is more tangible
in the liver than in other transplantation settings due to the
greater capacity of the liver allograft to cope with the cytolytic
effects of alloimmune responses [13,14]. The potential beneﬁts
of IS minimization or withdrawal, however, still need to be bal-
anced with the risks and inconveniences of prompting liver allo-
graft rejection. This assessment has to take into account the fact
that the individual recipient immunoreactivity evolves over time.
Over the past two decades, multiple studies on IS minimiza-
tion have been reported in the liver transplantation literature.
In parallel, a number of IS withdrawal trials have been performed.
While the results of some of these studies have been promising,
due to their heterogeneity and relatively small sample sizes, they
have failed to provide truly generalizable information. As a con-
sequence, we still lack evidence-based guidelines on how to
reduce IS to improve clinical outcomes, and therefore, the long-
term therapeutic management of liver transplant recipients
remains an empirical practice. We review the beneﬁts and limita-
tions of the different strategies employed in liver transplantation
to minimize or withdraw IS in an attempt to provide a framework
to critically assess and/or design future studies in the ﬁeld.Immunosuppression minimization
In the absence of accurate tools to determine the optimal level of
immunosuppression required by each individual patient, it is dif-
ﬁcult to objectively deﬁne ‘‘immunosuppression minimization’’.
A commonly used deﬁnition is the administration of the lowest
amount of immunosuppression compatible with a rejection-free
state [15]. The IS levels required to prevent rejection, however,
vary greatly, not only between different individuals, but also13 vol. 59 j 872–879
Table 1. Strategies to minimize immunosuppression.
Reference Minimization strategy N Study design Rejection Impact on co-morbidities
Margarit et al., [26] Steroid avoidance 60 Randomized
TAC vs. TAC + steroids
Acute rejection
39 vs. 32%; p = n.s.
No differences in survival rate and infections
Samonakis et al., [24] Steroid avoidance 56 Randomized
TAC vs. TAC + steroids + AZA
Acute rejection
70 vs. 86%; p = n.s.
No differences in renal function, metabolic complications and survival 
rate
Lerut et al., [25] Steroid avoidance 156 Randomized
TAC vs. TAC + steroids
Acute rejection
20 vs. 23%; p = n.s.
Steroid resistant
13 vs. 3%; p = 0.04
No differences in renal function, metabolic complications and PTLD
Herrero et al., [27] MMF 11 Progressive CNI reduction 
(6 patients free of CNI)
Acute rejection
2 episodes
Improvement in renal function in patients free of CNI
Schlitt et al., [28] MMF 28 MMF replacement vs. CNI Acute rejection
3 vs. 0 episodes
Orlando et al., [30] MMF 42 Conversion to MMF Acute rejection
9 patients
Renal function improved in 89% of the patients. Cholesterol and triglyc-
erides decreased in 76% of the patients. Blood pressure improved 80% 
of the patients
Abdelmalek et al., [36] Sirolimus 607 Randomized (2:1)
Conversion to sirolimus vs. CNI
Acute rejection
11 vs. 6%; p = 0.02
No differences in renal function or patients and graft survival
De Simone et al., [40] Everolimus 719 Randomized 1 month after LT
TAC + everolimus 
vs. everolimus vs. TAC
Acute rejection
4 vs. 11%; p = n.s.
Everolimus mono-
therapy was early 
terminated due to high 
rate of acute rejection 
(19%)
Improvement in renal function
Fischer et al., [39] Everolimus 203 Randomized 1 month after LT 
everolimus vs.TAC
Acute rejection
15 vs. 18%
No differences in renal function, infection or metabolic complications
Significant improvement in renal function in MMF patients. No differ-
ences in lipid profile and blood pressure
TAC, tacrolimus; AZA, azathioprine; PTLD, post-transplant lymphoproliferative disorder; CNI, calcineurin inhibitor; LT, liver transplant; n.s., not signiﬁcant.
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within the same individuals over time. Thus, to comply with this
deﬁnition, recipients would need to decrease IS doses until rejec-
tion occurs. A more useful deﬁnition of minimization is the
attainment of a state in which immunosuppressive drugs are
decreased down to levels that do not cause clinically signiﬁcant
side effects and yet prevent rejection. In liver transplantation, this
has been attempted by reducing CNI doses following induction
with T-cell depleting agents, by avoiding steroids and administer-
ing CNIs on monotherapy, or by withdrawing CNIs at later time
points (Table 1). In addition, a variety of trials designed to pre-
vent speciﬁc side effects (e.g., diabetes, renal failure) by combin-
ing various IS drugs at reduced doses have also been performed,
but these do not fall within the scope of what would be consid-
ered drug minimization. An important consideration when
assessing these studies is the fact that the standard recom-
mended CNI dosing targets for liver transplantation were origi-
nally set within clinical trials that replicated the doses
employed in kidney transplantation, where overall immunosup-
pression requirements are higher than in liver transplantation.
The optimal ranges for CNI levels in liver transplantation have
not been studied in depth and are still unclear.CNI minimization and induction with T-cell depleting
antibodies early after LT
The use of T-cell depleting therapies in combination with drasti-
cally reduced CNI doses has been proposed as a strategy poten-
tially capable of maximizing the tolerogenic properties of liver
allografts [16] by achieving a ‘‘prope’’ tolerant state in which nor-
mal graft function is maintained with minimal (spaced-dose)
immunosuppression [16,17]. Starzl et al. [16] ﬁrst reported the
results of this strategy in liver transplant recipients in 2003. In
this study, a single pre-transplant dose of thymoglobulin was
administered followed by monotherapy with tacrolimus at doses
that were gradually decreased, starting 4 months after transplan-
tation. The trial was successful in that 11 out of the 14 survivors,
13–17 months after transplantation, were receiving spaced-dose
tacrolimus administration (every other day) with very low blood
levels. The real applicability of the strategy was however difﬁcult
to ascertain, since a very large number of protocol violations
occurred. Furthermore, the rejection rate and response to therapy
were not clearly described. The same group performed a subse-
quent cohort study in which they compared 76 liver patients
treated with alemtuzumab and tacrolimus monotherapy fol-
lowed by gradual tapering of tacrolimus doses with a cohort of
84 patients who received tacrolimus plus steroids at conven-
tional doses. At 14 to 22 months after transplantation, 62% of sur-
viving alemtuzumab-treated recipients were on spaced dosed
tacrolimus, and this was achieved without an increased rate of
rejection. In this study, hepatitis C virus (HCV+) infection was
associated with very low patient and graft 1-year survival,
regardless of the treatment arm (70% and 71% in alemtuzumab-
treated patients and 65% and 54% in patients under conventional
treatment) [18]. By contrast, De Ruvo et al. [19] retrospectively
compared 22 HCV+ liver transplant recipients treated with thy-
moglobulin and tacrolimus monotherapy to 30 HCV+ patients
under standard immunosuppression (tacrolimus plus steroids).
Patients treated with thymoglobulin achieved lower tacrolimus
trough levels and this was not associated with increased mortal-
ity, rejection episodes, or severity of HCV recurrence [19].874 Journal of Hepatology 201Whether this resulted in clinical beneﬁts (e.g., improved renal
function or decreased metabolic co-morbidities) was, however,
not reported. Benitez et al. performed a randomized controlled
trial (RCT) in which recipients were allocated to either conven-
tional immunosuppression (tacrolimus plus steroids) or to induc-
tion with ATG-Fresenius followed by tacrolimus monotherapy. In
the experimental group, tacrolimus doses were gradually
decreased starting 3 months after transplantation to achieve
spaced dose administration or single day doses with <5 ng/ml
trough levels. Patients treated with the experimental regimen
received lower tacrolimus and steroid doses, but this was associ-
ated with an increased rate of early acute rejection episodes (66%
vs. 31% in the control group). Furthermore, at 3 months after
transplantation, only a minority of ATG-treated recipients met
the criteria for partial tacrolimus weaning, and in those in whom
weaning was attempted, the development of late acute rejection
episodes precluded the attainment of the primary end point.
Once more, obvious clinical beneﬁts in terms of decreased immu-
nosuppression-related adverse events were not seen [20].
Altogether, it is clear from these studies that the use of T-cell
depleting therapies allows for an overall reduction in the doses of
conventional immunosuppressive drugs. Anecdotally, this treat-
ment can facilitate the complete discontinuation of immunosup-
pression [21]. However, high rejection rates may occur when
immunosuppressive drugs are rapidly reduced. Furthermore,
whether aggressive T-cell depletion should be included under
the scope of what is considered IS minimization is unclear, in par-
ticular following alemtuzumab treatment, whose immunosup-
pressive effects can last for years. Whether the strategy results
in clinical beneﬁts has not been formally demonstrated yet. These
studies need to be assessed in the light of recent reports indicat-
ing that CNI trough levels lower than those traditionally recom-
mended (i.e., tacrolimus 10–15 ng/ml during the ﬁrst month
after transplantation) can be achieved within conventional
immunosuppressive regimens, resulting in improved clinical out-
comes without increasing rejection [10,22].Steroid minimization or avoidance
Steroid-free immunosuppressive regimens and early steroidwith-
drawal protocols have been explored inmultiple RCTs, 21 ofwhich
were included in a recent meta-analysis [23]. In 18 out of the 21
studies included in the meta-analysis, no attempt at immunosup-
pressionminimizationwasmade in that steroidswere replaced by
other immunosuppressive agents (daclizumab, thymoglobulin,
mycophenolate mofetil [MMF], or basiliximab). The 3 remaining
studies [24–26], by contrast, directly compared standard immuno-
suppression (tacrolimus plus steroids ± azathioprine) with tacrol-
imus monotherapy. Overall, steroid-free cohorts exhibited
decreased development of de novo diabetesmellitus, lower choles-
terol levels, and lower incidence of cytomegalovirus infection.
These beneﬁts were not observed in the 3 trials that speciﬁcally
analysed clinical outcomes following tacrolimus monotherapy.
Margarit et al. [26] randomized 60 patients to receive tacrolimus
monotherapy or tacrolimus plus steroids. Survival rate, acute
rejection incidence, infections, and side effects were comparable
between the 2 groups of treatment. A separate analysis of HCV+
patients showed a signiﬁcantly lower Ishak ﬁbrosis score in the
tacrolimus monotherapy group. Samonakis et al. [24] randomized
56 HCV+ patients to tacrolimus monotherapy or triple therapy3 vol. 59 j 872–879
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(tacrolimus, steroids and azathioprine). There were no differences
between the 2 groups in rejection, renal dysfunction, metabolic
complications, retransplantation, and survival rates. Lerut et al.
[25] prospectively randomized 156 patients to tacrolimus mono-
therapy of tacrolimus plus a short steroid course. There were no
differences between the 2 groups in the overall incidence of acute
rejection, albeit steroid-resistant rejectionwas higher in recipients
treated with tacrolimus monotherapy (12.8% vs. 3.8%, p = 0.04).
Again, no differences in metabolic complications, infections, and
1-year survival were observed. Taken together, these results sug-
gest that clinical outcomes following tacrolimus monotherapy
are fully comparable to those obtained with more ‘‘conventional’’
immunosuppressive regimens. Despite this, the use of tacrolimus
as monotherapy has not been further explored and remains mar-
ginal within the current state of immunosuppressive therapy. This
is likely due to the current emphasis on preventing renal dysfunc-
tion by reducing CNIs rather than steroids [9].Minimization of CNIs at late time points after transplantation
Employment of MMF to reduce CNI exposure
Given the association between chronic renal dysfunction and
decreased recipient survival, most attempts at drug minimization
conducted at late time points after transplantation have focused on
the reduction or substitution of CNIs. The ﬁrst attempts to minimize
CNIs in long-termsurviving liver recipients employedMMF to reduce
CNI exposure. Herrero et al. [27] ﬁrst described the effect of adminis-
tering MMF to 11 recipients with impaired kidney function as a
means to reduce CsA dosing. Patients who were free from CsA expe-
rienced a reduction in serum creatinine and increased creatinine
clearance. Comparable results were reported by Schlitt et al. [28].
Patientswhowere switched fromCNIs toMMF improved renal func-
tion, arterial blood pressure, and uric acid as compared with control
patients on CNI. Three patients in the group on monotherapy with
MMF developed acute rejection. Pageaux et al. [29] employed the
same strategy within an RCT that recruited 56 liver recipients with
renal dysfunction. A switch to low-dose CNI (>50% dose reduction)
plus MMF was associated with an improvement in renal function at
12 months without an increase in the incidence of acute rejection
[29]. Orlando et al. converted 42 long-term recipients on CNImainte-
nance IS (mostly cyclosporine A) with renal dysfunction, hyperten-
sion or hyperlipidemia to MMF monotherapy. This resulted in
improvements in renal function, cholesterol and triglyceride levels
and/or blood pressure levels in approximately 80% of the cases
[30]. By contrast, in a retrospective study, involving 1075 patients
in which chronic renal dysfunction was identiﬁed as a risk factor
for decreased survival within the ﬁrst year of transplantation,
CNI reductionandadditionofMMF inpatientswithadvanced renal
dysfunction did not improve creatinine levels [31].
Employment of mTOR inhibitors to reduce CNI exposure
A number of single-centre studies employing mTOR (mammalian
target of rapamycin) inhibitors as replacement for CNIs to improve
renal function have been performed. Results ranged from no beneﬁt
[32–34] to mild increases in glomerular ﬁltration rate [33–35].
Abdelmalek et al. [36] recently published the results of the ﬁrst mul-
ticentre prospective RCT evaluating safety and efﬁcacy of sirolimus
conversion in liver recipients 6 months after liver transplantation.
No signiﬁcant differences in renal function between patientsJournal of Hepatology 201switched to sirolimus and those maintained on CNIs were observed.
Furthermore, sirolimus conversion was associated with increased
rejection and treatment discontinuation. The latter was probably
related to the fact that the sirolimus doses employed in the study
were signiﬁcantly higher than those commonly used in clinical prac-
tice [37]. Conversion to everolimus has also been analyzed in a few
prospective randomized studies. De Simone et al. randomized 145
patients tocontinueCNIexposure (n = 72)orCNI reductionordiscon-
tinuation (n = 73). At 6 months, 80% of the patients on everolimus
stopped CNIs. Everolimus conversionwas safe but therewere no sig-
niﬁcant improvement in renal function in patientswithout CNIs [38].
Fischer et al. published a prospective randomized study to evaluate
the efﬁcacy and safety of conversion to everolimus in renal function.
Four weeks after LT, patients were randomized to continue CNI or to
convert to everolimus. Therewerenodifferencesbetween thegroups
of patients in termsof acute rejectionormortality.However, at 1 year
of conversion, the authorwere not able to ﬁnd a signiﬁcant improve-
ment in renal function inpatients converted to everolimus [39].More
recently, De Simone reported the results of a prospective trial in
which de novo liver transplant recipients were randomized to tacrol-
imus elimination after everolimus introduction, everolimus plus
reduced dose tacrolimus, and standard-dose tacrolimus. The everol-
imus plus low-dose tacrolimus grouppresentedbetter renal function
as compared with standard-dose tacrolimus. However, the tacroli-
mus elimination group was prematurely stopped due to high rate
of acute rejection [40]. Conversion to mTOR inhibitors could have
anadditionalbeneﬁcial effectby favouring theexpansionof immuno-
regulatory T cells [41–43], which in experimental animalmodels has
been linked to transplantation tolerance. Thus, Levitsky et al. [42]
described an increase in the number of regulatory T cells following
conversion from tacrolimus to sirolimus. Whether these changes
would favour successful discontinuation of immunosuppression in
human liver recipients is however currently unknown.
Altogether the overall clinical beneﬁts of CNI minimization at
late time points after transplantation are still unclear. While in
some circumstances a renal-sparing effect is observed, there is
almost no data on whether late CNI minimization inﬂuences
other clinical end points. Furthermore, the potential impact of
IS minimization protocols on long-term subclinical histological
graft damage (e.g., idiopathic chronic hepatitis and/or progressive
ﬁbrosis) also remains to be properly investigated [44]. This is rel-
evant considering that most protocol biopsy studies have
revealed substantial histological abnormalities in long-term sur-
viving liver recipients with unremarkable liver function tests
[44–47]. The likelihood of improving renal function and other
co-morbidities is probably higher if CNIs are minimized early
after transplantation (i.e., within 2 years of transplantation).
The risk of rejection early after transplantation is, however,
higher than at late time points.Immunosuppression withdrawal
The notion that immunosuppressive drugs can be completely dis-
continued from selected liver recipients has been known for more
than two decades [48]. These patients, who maintain normal graft
function in the absence of histological signs of progressive graft
damage anddonot exhibitmanifestations of immunocompromise,
are conventionally referred to as operationally tolerant [49]. Fol-
lowing the original report from Starzl et al. in 1993 describing
the cases of 6 non-compliant patients who discontinued immuno-
suppression and yet maintained normal liver function for 5–3 vol. 59 j 872–879 875
Table 2. Spontaneous operational tolerance in liver transplantation: clinical experience with elective IS weaning.
Reference n Time since 
transplantation (yr)
IS withdrawal 
(%)
Acute rejection 
(%)
Chronic rejection 
(%)
Graft loss 
(%)
Mazariegos et al., [50] 95 8.4 (1.7-25) 19 26 0 0
Devlin et al., [51]
Girlanda et al., [52]
18 6.5 (5-10) 16.7 28 5.6 5.6
Takatsuki et al., [53] 26 >2 23.8 12 0 0
Eason et al., [54] 18 >6 mo 5.6 61 0 0
Tryphonopoulus et al., [55] 104 4 19 67 1.9 0.96
Tissone et al., [56] 34 5.3 23.4 76.4 0 0
Assy et al., [57] 26 4.6 8 58 0 0
Pons et al., [58] 21 5.2 (24-127) 38 22 0 0
Feng et al., [64] 20 7.6 (4.4-12.7) 60 35 0 0
Benitez et al., [66] 102 8.5 (3-19) 40.2 59.8 0 0
Frontiers in Liver Transplantation13 years [48], several reports describing retrospective and/or
single-centre experiences with immunosuppression withdrawal
were published (Table 2) [14,50–59]. On the basis of these studies,
a 20% prevalence of operational tolerance in liver transplantation
was proposed [60], although this estimate did not take into consid-
eration the heterogeneity of the study designs and of the criteria
employed to select andenrol patients. The incidence of acute rejec-
tion episodes within these studies was very high. These episodes,
however, were in most cases mild, and often resolved by return
to baseline IS without administration of steroid boluses. Reassur-
ingly, only 2 cases of graft loss due to chronic rejection among
patients involved in these IS weaning protocols were reported
[52,55]. The long-term histological outcome of drug-free liver
recipients was, however, difﬁcult to assess due to small sample
sizes and/or lack of sequential protocol biopsies. In most studies,
patients off immunosuppression exhibited no obvious progressive
liver histological damage. Yoshitomi et al. [61], however, reported
slightly increased ﬁbrosis progression in operationally tolerant
recipients as compared with patients under maintenance immu-
nosuppression, although the lack of pre-weaning liver biopsies
and marked differences in post-transplant follow-up between
cases and controls reduced the robustness of the study. The poten-
tial clinical beneﬁt of drug withdrawal was also only partially
explored. Thus, after a mean follow-up of 6.5 years, Orlando et al.
reported that a small group of 7 tolerant recipients exhibited
decreased HCV-RNA levels, reduced infection rate, and less medi-
cation requirement to treat co-morbidities than the 22 patients
who remained under maintenance IS [62]. No differences were,
however, noted in terms of ﬁbrosis stage, ﬁbrosis progression rate,
and necro-infammatory activity. In a parallel study by Pons et al.
with a similarly prolonged drug-free follow-up (range 43–
132 months), a group of 8 tolerant liver recipients exhibited signif-
icant improvements in creatinine, glucose, anduric acid serum lev-
els as compared with the 12 recipients in whom drug withdrawal
failed [63]. Overall, these studies demonstrated the feasibility of
discontinuing IS fromstable liver recipients, but small sample sizes
and/or lack of homogeneous well-standardized algorithms for
patient screening, drug withdrawal, and patient follow-up some-
how reduced the generation of truly generalizable information.
The recent reports of the ﬁrst two prospective multi-centre and
independently monitored clinical trials of IS withdrawal in paedi-
atric and adult liver recipients, respectively [64–67], have
addressed someof the limitations of previous studies. The paediat-
ric multi-centre study [64], sponsored by the Immune Tolerance
Network in the US, included 20 carefully selected recipients of876 Journal of Hepatology 201parental living donor liver transplants in whom IS was prospec-
tively withdrawn over approximately 36 weeks. Drug withdrawal
was successful in 12 recipients,whomaintainednormal graft func-
tion after at least 1 year following complete IS discontinuation, and
in whom liver biopsies obtained more than 2 years after complete
IS withdrawal showed no signiﬁcant change compared with base-
line biopsies. The most signiﬁcant clinical factor associated with
successful IS withdrawal was an increased time interval between
transplantation and initiation of IS weaning (100.6 months in
operationally tolerant vs. 73 months in thosewho failed to discon-
tinue IS; p = 0.03). No patient developed irreversible graft damage.
However, the beneﬁcial effect of drug withdrawal could not be
adequately assessed. The adult multi-centre study supported by
the European Union RISET Consortium enrolled 102 adult recipi-
ents in whom IS were gradually discontinued over 6 to 9 months
[65]. Forty-two patients were successfully weaned, maintained
stable graft function for at least 12 months after drug withdrawal,
and exhibited no signs of rejection in protocol liver biopsies
obtained 12 months following withdrawal. The successful discon-
tinuationof ISwas associatedwith longerduration after transplan-
tation, more advanced age of the recipients at the time of
transplant, and male gender. The effect of time after transplanta-
tion was surprisingly strong, in that a striking 79% of recipients
enrolled in the study more than 10.6 years after transplant could
be successfully wean from IS, while this occurred in <15% of those
transplanted for less than 6 years [67]. No signiﬁcant beneﬁcial
effect of IS withdrawal on renal function, hypertension, diabetes,
and hyperlipidemia was however noted.
Preliminary data from an on-going US randomized adult
multi-centre trial in which IS withdrawal was initiated within
the second year after transplantation, further supports the notion
that time after transplantation is a critical parameter associated
with successful drug withdrawal. At the time these results were
reported in 2011, 67 adult recipients had been enrolled in the
study, 53 of whom were randomized to IS withdrawal and 14
to maintain conventional IS. In contrast to the two studies
described above, IS withdrawal was successful in only 2 out of
the 18 patients in whom IS withdrawal was attempted [68].Immunosuppression withdrawal in hepatitis C positive
patients
The course of hepatitis C recurrence is inﬂuenced, among other
factors, by the strength of IS. Several factors support this3 vol. 59 j 872–879
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statement. Fibrosing cholestatic hepatitis, the most severe pre-
sentation of hepatitis C recurrence, has only been described in
immunosuppressed patients. Besides, it is well known that the
rate of ﬁbrosis progression is higher in immunosuppressed
patients and in HIV-co-infected patients [69]. Steroid boluses
to treat rejection are clearly associated with higher viral load,
earlier and more severe HC recurrence, and higher liver-related
mortality [70]. Beyond this, however, the role of speciﬁc IS
agents is difﬁcult to assess, with most of the published studies
being retrospective and lacking long follow-ups and/or protocol
biopsies [69,71,72]. Overall, the global immunosuppressive sta-
tus appears to be more important than the effects of individual
drugs. For instance, Berenguer et al. [73] showed that when
over-IS was avoided (steroid boluses and triple or quadruple
therapies), the rate of severe HC recurrence decreased from
54% to 33%.
On thebasis of these evidence, ISwithdrawal couldbeneﬁt hep-
atitis C recipientsbydelaying theprogressionof viral-induced liver
damage. IS withdrawal is indeed feasible in hepatitis C positive
patients [51,52,54,55], The impact of drugwithdrawal on hepatitis
C disease progression, however, has only been formally investi-
gated by the Tor Vergata group in Rome [56]. The authors evalu-
ated 34 hepatitis C positive liver transplant recipients with more
that 1 year after transplantation and normal liver function.
Twenty-four percent of the patients achieved an IS-free state. After
3 years of follow-up, operational tolerant recipients showed a sig-
niﬁcant reduction in ﬁbrosis progression (ﬁbrosis progression rate
of 0.16 ± 0.19 vs. +0.16 ± 0.31 in patients who developed rejec-
tion and needed to bemaintained on IS; p = 0.0098). After 10 years
of follow-up, however, ﬁbrosis progression was comparable
between the 2 groups and tolerant patients showed only a trend
towards slower progression rate (0.26 ± 0.16 vs. 0.48 ± 0.16;
p = 0.06) and slightly lower Ishak ﬁbrosis score (1.5 ± 0.9 vs.
2.8 ± 1.5; p = 0.07) [74]. There were no signiﬁcant differences
between the 2 groups regarding renal function, diabetes, cardio-
vascular complications, and lipid proﬁle.
Key Points
• Transplant recipients exhibit higher morbidity and 
mortality as compared to the general population. 
Co-morbidities related to the chronic use of 
immunosuppression are one of the main causes
 
• Immunosuppression minimization is desirable in liver
transplant recipients
• No minimization strategy (T-cell depleting agents, 
steroid avoidance, or CNIs reduction) has been proved
to be superior and prospective randomized trials are
needed
• Immunosuppression drug withdrawal is feasible in 
liver transplant recipients. However, a potential clinical
benefit of completely withdrawing immunosuppression
has not been clearly demonstrated and the long-
term histological stability of the operational tolerance
phenotype is still unclear
• Currently, there is no clear justification  to discontinue IS
outside of carefully monitored clinical trialsJournal of Hepatology 201ConclusionsWhile there is a general perception that a large proportion of
liver recipients are over-immunosuppressed, how to minimize
immunosuppression in order to improve clinical outcomes
remains unclear. Recent reports have shown that lower tacroli-
mus trough concentrations early after transplantation are associ-
ated with improved renal function [22], and in some cases with
longer graft survival [10]. Many of these studies, however,
achieved reduced CNI levels by employing ‘‘cocktail’’ multi-drug
IS regimens. These regimens cannot be considered IS minimiza-
tion per se, albeit this cannot be conﬁrmed in the absence of reli-
able tools to individually quantify the overall degree of
immunosuppression. On the other hand, what have been tradi-
tionally considered bona ﬁde IS minimization strategies (i.e., the
reduction or avoidance of CNI and/or steroids in the absence of
additional IS drugs), have yielded inconsistent results [75–77].
Some studies showed moderate improvement in renal function
and/or metabolic complications, but others reported no signiﬁ-
cant clinical beneﬁts. This is not entirely surprising considering
that several of these studies were poorly designed and inade-
quately powered. Impact on hard clinical outcomes (i.e., survival)
has not been intentionally investigated. There is a clear need
therefore for large clinical trials of IS minimization conducted
at relatively early time points after transplantation and focused
on clinically-relevant long-term outcomes. Long-term effects on
liver histology would need to be investigated in parallel to unam-
biguously determine if IS minimization is associated with idio-
pathic inﬂammatory and ﬁbrotic lesions.
The recent multi-centre IS withdrawal trials have unambigu-
ously established that drug weaning can be conducted according
to standardized protocols with good short-term results. Further-
more, they have demonstrated that time is the most important
parameter inﬂuencing the development of operational tolerance.
This ﬁnding will certainly shape future trials of drug withdrawal.
A potential clinical beneﬁt of completely withdrawing immuno-
suppression, however, has not been clearly demonstrated. This
is not unexpected, considering the small sample sizes of most
studies and their still limited patient follow-up. On the other
hand, beneﬁts might not be apparent unless drug withdrawal is
achieved much earlier after transplantation, before long-term
exposure to immunosuppression-related toxicities has occurred.
In order to achieve this, however, effective tolerance-promoting
strategies such as those recently employed in kidney transplanta-
tion [78] would need to be employed, which is currently difﬁcult
to envisage in their current from given their inherent toxicity and
the poor clinical state of most liver recipients at the time of trans-
plantation. An additional issue to clarify is the long-term histo-
logical stability of the operational tolerance phenotype. Given
the lack of obvious clinical beneﬁts, uncertainties regarding
long-term histological outcomes, and the high rate of rejection
associated with IS withdrawal in unmanipulated liver recipients
even when conducted very late after transplantation, no clear jus-
tiﬁcation currently exists to discontinue IS outside of carefully
monitored clinical trials. Indeed, the mechanistic insight pro-
vided by these studies has been so far their most valuable contri-
bution. If validated in future trials, this information might open
the door to novel therapeutic approaches. Furthermore, conﬁr-
mation that operational tolerance can be predicted employing a
combination of clinical parameters and molecular biomarkers3 vol. 59 j 872–879 877
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would modify the equipoise in favour of discontinuing IS in
previously identiﬁed operationally tolerant recipients. The avail-
ability of accurate biomarkers of tolerance would also facilitate
the implementation of novel immunotherapeutic strategies such
as the use of immunoregulatory cell therapy.Conﬂict of interest
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